VITAL is happy to announce a new non-dilutive funding opportunity supporting advancements in long-acting monoclonal antibody and/or nucleic acid-based platforms for pre-exposure prophylaxis (PrEP) for seasonal and pandemic influenza and other respiratory viruses. Start2 and BARDA established VITAL – a BARDA Accelerator Network (BAN) hub providing non-dilutive funding and accelerator program support for innovations in vaccines and therapeutics targeting infectious diseases.
VITAL seeks innovations that improve delivery, biodistribution, half-life extension, and durability of vaccines and therapeutics. VITAL now has a NEW FUNDING SOLICITATION for up to $7.5M over 3 years. The solicitation is OPEN NOW, and accepting applications from academic innovators and startups from Europe, the U.S., and Asia! More detailed information is found on VITAL’s website here.
This new solicitation supports advancements of monoclonal antibody (mAbs) and nucleic acid platforms for pre-exposure prophylaxis (PrEP) for influenza and other respiratory viruses. More detailed information about this PrEP funding opportunity is provided on the VITAL website and in this document “VITAL prep funding solicitation autumn 2024 – final.pdf”. Additionally, information about VITAL in general and all the funding and program opportunities we provide is found in another document: “VITAL overview oct 2024.pdf”.
VITAL, managed by Start2 Group (a German Accelerator program), is a new BARDA Accelerator Network (BAN) hub providing non-dilutive funding and accelerator program support for innovations in vaccines and therapeutics targeting infectious diseases.